Spyre Therapeutics, Inc. Common Stock SYRE

$93.93 +0.35% at last close

Recent SEC Filings

FormDescriptionFiledDocument
8-K 8-K 2026-08-25 View →
4 FORM 4 2026-08-10 View →
4 FORM 4 2026-08-05 View →
4 FORM 4 2026-08-05 View →
8-K 8-K 2026-08-04 View →
10-Q 10-Q 2026-08-04 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-07-02 View →
4 FORM 4 2026-06-26 View →
4 OWNERSHIP DOCUMENT 2026-06-23 View →
4 FORM 4 2026-06-23 View →
8-K 8-K 2026-06-15 View →
4 FORM 4 2026-06-03 View →
4 FORM 4 2026-06-03 View →
4 FORM 4 2026-06-03 View →
8-K 8-K 2026-06-01 View →
4 FORM 4 2026-05-29 View →
4 FORM 4 2026-05-29 View →
4 FORM 4 2026-05-29 View →
4 FORM 4 2026-05-29 View →
4 FORM 4 2026-05-29 View →
4 FORM 4 2026-05-29 View →
8-K 8-K 2026-05-29 View →
4 FORM 4 2026-05-08 View →
8-K 8-K 2026-05-05 View →
10-Q 10-Q 2026-05-05 View →
4 FORM 4 2026-05-01 View →
4 FORM 4 2026-05-01 View →
4 FORM 4 2026-05-01 View →
8-K 8-K 2026-04-16 View →
424B5 424B5 2026-04-16 View →
424B5 424B5 2026-04-13 View →
8-K 8-K 2026-04-13 View →
8-K 8-K 2026-04-13 View →
DEF 14A DEF 14A 2026-04-10 View →
4 FORM 4 2026-04-03 View →
4 FORM 4 2026-04-03 View →
4 FORM 4 2026-04-03 View →
4 FORM 4 2026-03-03 View →

Filings are sourced directly from the SEC's EDGAR system. Annual reports (10-K) and quarterly reports (10-Q) carry the full financial statements; 8-K filings disclose material events between reports; Form 4 filings record insider purchases and sales.

Key Stats

Last Close
$93.93
Market Cap
$8.25 billion
52-Week Range
$14.51 – $110.17
Average Volume
903K shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.